Novartis Investigative Site

Jacksonville, Florida 32256

0 studies enrolling now · 45 studies all time

What they study most

Acute Decompensated Heart Failure, Acute Heart Failure, Alzheimers Disease, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atherosclerotic Coronary Vascular Disease, Carcinoma, Renal Cell, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Chronic Ocular Pain, Congestive Heart Failure

Studies at this site

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease — Stopped early
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) — Completed
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus — Completed
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol — Completed
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
Safety Study of LLF580 in Obese Volunteers — Completed
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod — Completed
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo — Completed
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) — Stopped early
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease — Stopped early
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication — Completed
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. — Completed
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients — Completed
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) — Completed
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder — Completed
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder — Completed
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer — Completed
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia — Completed
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles — Stopped early
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure — Completed
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients — Completed
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension — Completed
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis — Completed
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis — Completed
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed